Market penetration of new drugs in one United Kingdom region: implications for general practitioners and administrators.
about
The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort studyInfection and antimicrobial prescribing control in the new millennium: nightmare or nirvana?Antibiotic resistance: a growing and multifaceted problem.Not so simple cystitis: how should prescribers be supported to make informed decisions about the increasing prevalence of infections caused by drug-resistant bacteria?A qualitative study to explore influences on general practitioners' decisions to prescribe new drugs.General practitioners' adoption of new drugs and previous prescribing of drugs belonging to the same therapeutic class: a pharmacoepidemiological study.Prevalence of anti-ulcer drug use in a Chinese cohortMeasuring prescribing: the shortcomings of the itemDid knowledge, opinions, background, and health authority advice influence early prescribing of the novel Alzheimer's disease drug donepezil in general practice?--national postal survey.Pathways for inappropriate dispensing of antibiotics for rhinosinusitis: a randomized trial.Growth in the use of antibiotics in the community in England and Scotland in 1980-93.Formulary revision: eliciting the opinions of users.Reasons for not seeing drug representatives.Market penetration of new drugs. Increased prescribing may be appropriate.Market penetration of new drugs. Compare Britain with other national markets.Patient knowledge and prescription of ulcer healing drugs in medical inpatients.Market penetration of new drugs.Antibiotic prescribing for respiratory tract infections in general practice.Impact of remifentanil introduction on practice patterns in general anesthesia.The use of drugs is not as rational as we believe… but it can't be! The emotional roots of prescribing.
P2860
Q33333061-5CEEB787-276B-491F-BE3E-624E250CC608Q33893062-D3B62090-8C4E-438E-88E6-D1029A182E79Q34061340-386AAEE8-0568-4B57-B285-EAEB549664FBQ34218096-37199A71-C294-43C3-BC4B-ABE90F993C78Q34223086-A28BDAE7-8B36-4C3F-8784-2E5DC959731BQ35827238-1C6877BC-64A6-4F10-AE52-E4612C8BA320Q36179882-9AB156D5-BEE5-461B-B61A-CD37E11D18D9Q36884667-D4BA0634-D09E-4A1A-87E9-4FAF32CCB7FFQ40518584-897DE8AC-B155-4C50-96F2-42C8E8E2CCA0Q40601967-E62B5B10-C4E7-4C05-9E2F-0B8750DF8918Q41826026-2C883661-A34A-46F7-986B-4DDB57AB8001Q42547871-6430D1E5-3A44-46DA-9EC1-F8F2ABB57B27Q42763354-F2A76E7A-B14B-4482-A22D-5DC28FF6318AQ43150492-2617EE29-02C2-454B-82D8-D6A0B8F30AD0Q43150508-B37D52BA-F9D1-4162-A589-88B4D456FE88Q43201802-6CED46BB-3E8B-4C13-80BA-EA8E1B3D4A87Q46200539-E849E739-0B9D-48D7-9B75-7A528D5A0595Q47995581-AE2E361C-3930-4F73-A81C-1876DFB1D301Q48232400-71C8190D-48A5-440B-8690-7BBEF33884FBQ50637161-252A7CEE-1992-444A-8F2A-658C690D0DE3
P2860
Market penetration of new drugs in one United Kingdom region: implications for general practitioners and administrators.
description
1993 nî lūn-bûn
@nan
1993 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Market penetration of new drug ...... ctitioners and administrators.
@ast
Market penetration of new drug ...... ctitioners and administrators.
@en
type
label
Market penetration of new drug ...... ctitioners and administrators.
@ast
Market penetration of new drug ...... ctitioners and administrators.
@en
prefLabel
Market penetration of new drug ...... ctitioners and administrators.
@ast
Market penetration of new drug ...... ctitioners and administrators.
@en
P2093
P2860
P1433
P1476
Market penetration of new drug ...... ctitioners and administrators.
@en
P2093
P2860
P304
P356
10.1136/BMJ.307.6912.1118
P407
P577
1993-10-01T00:00:00Z